EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions

Shashwat Tripathi, Cody L Nathan, Matthew C Tate, Craig M Horbinski, Jessica W Templer, Joshua M Rosenow, Timothy L Sita, Charles D James, Benjamin Deneen, Stephen D Miller, Amy B Heimberger

JCI Insight · 09.01.2024 · 9 (1)

DOI: 10.1172/jci.insight.174753 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCI Insight, online erschienen am 09.01.2024. Verfasst von Shashwat Tripathi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery. Hauptthemen laut MEDLINE: Epilepsy, Glioma, Drug Resistant Epilepsy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy has a profound impact on quality of life. Despite the development of new antiseizure medications (ASMs), approximately one-third of affected patients have drug-refractory epilepsy and are nonresponsive to medical treatment. Nearly all currently approved ASMs target neuronal activity through ion channel modulation. Recent human and animal model studies have implicated new immunotherapeutic and metabolomic approaches that may benefit patients with epilepsy. In this Review, we detail the proinflammatory immune landscape of epilepsy and contrast this with the immunosuppressive microenvironment in patients with glioma-related epilepsy. In the tumor setting, excessive neuronal activity facilitates immunosuppression, thereby contributing to subsequent glioma progression. Metabolic modulation of the IDH1-mutant pathway provides a dual pathway for reversing immune suppression and dampening seizure activity. Elucidating the relationship between neurons and immunoreactivity is an area for the prioritization and development of the next era of ASMs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyGliomaDrug Resistant EpilepsyAnimalsHumansQuality of LifeImmune SystemTumor Microenvironment

Autor:innen und Institutionen

  • Department of Neurological Surgery.
  • Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center.
  • Department of Neurology.
  • Department of Pathology, and.
  • Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Tripathi, S., Nathan, C. L., Tate, M. C., Horbinski, C. M., Templer, J. W., Rosenow, J. M., Sita, T. L., James, C. D., Deneen, B., Miller, S. D., & Heimberger, A. B. (2024). The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions. JCI Insight, 9(1). https://doi.org/10.1172/jci.insight.174753

Vancouver

Tripathi S, Nathan CL, Tate MC, Horbinski CM, Templer JW, Rosenow JM, et al. The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions. JCI Insight. 2024;9(1). doi:10.1172/jci.insight.174753

BibTeX
@article{Tripathi2024,
  author = {Tripathi, Shashwat and Nathan, Cody L and Tate, Matthew C and Horbinski, Craig M and Templer, Jessica W and Rosenow, Joshua M and Sita, Timothy L and James, Charles D and Deneen, Benjamin and Miller, Stephen D and Heimberger, Amy B},
  title = {The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions},
  journal = {JCI Insight},
  year = {2024},
  volume = {9},
  number = {1},
  doi = {10.1172/jci.insight.174753}
}
Kostenlos starten →